These findings suggest that Parkin regulates mitochondrial hemostasis and energy metabolism in WAT, suggesting that Parkin is a viable therapeutic target to combat obesity and obesity-associated disorders. This evidence concerns the gene PRKN and obesity due to melanocortin 4 receptor deficiency.